Eczema Cured » Arthritis / Rheumatology

NICE Final Draft Guidance Recommends Improved Access To Psoriatic Arthritis Treatments

Eczema / Psoriasis News From Medical News Today — Wed, 16 Jun 2010 20:00:00 +0000

Three treatments for psoriatic arthritis are recommended in final draft guidance published by the National Institute of Health and Clinical Excellence (NICE). Etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) are proposed for treating adults with active and progressive psoriatic arthritis when specified criteria are met...

NICE Draft Guidance Proposes Treatment Options For Psoriatic Arthritis

Eczema / Psoriasis News From Medical News Today — Tue, 16 Mar 2010 07:00:00 +0000

The National Institute for Health and Clinical Excellence (NICE) has published draft guidance recommending etanercept (Enbrel, Wyeth Pharmaceuticals) and adalimumab (Humira, Abbott Laboratories) for the treatment of adults with active and progressive psoriatic arthritis when specific criteria are met...

What Is Enbrel (Etanercept)? What Is Enbrel Used For?

Eczema / Psoriasis News From Medical News Today — Tue, 23 Feb 2010 08:00:00 +0000

Enbrel is the trade name for Etanercept, a medication used for treating autoimmune diseases. Enbrel is a TNF (tumor necrosis factor) inhibitor; it interferes with TNF…

Share and Enjoy:

Wyeth Launches New Innovative Delivery System For Enbrel(R) (etanercept)

Eczema / Psoriasis News From Medical News Today — Sun, 13 Sep 2009 08:00:00 +0000

Enbrel (etanercept), Wyeth's biological treatment for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis, is now available as a new easy-to-use pre-filled auto-injector device, known as the Enbrel MYCLIC pen. The Enbrel MYCLIC pen is a single-use auto-injector, designed to deliver Enbrel as a 50mg subcutaneous injection...

Wyeth Launches New Innovative Delivery System For Enbrel(R) (etanercept)

Eczema / Psoriasis News From Medical News Today — Sun, 13 Sep 2009 08:00:00 +0000

Psoriatic Arthritis: New Drug Shows Promising Results

Eczema / Psoriasis News From Medical News Today — Sat, 11 Apr 2009 08:00:00 +0000

Psoriatic arthritis affects about 11 percent of patients with psoriasis. Anti-tumor necrosis factor Î± (anti-TNFÎ±) agents, which block signaling molecules that induce inflammation, improve the symptoms of psoriatic arthritis. Golimumab is a new human monoclonal antibody that works against TNFÎ± and has been shown to be beneficial within two weeks of the first subcutaneous injection in a phase II rheumatoid arthritis trial.